Food Allergy Treatment Market Companies
- Johnson & Johnson
- Sanofi
- Novartis Pharmaceuticals
- Aimmune Therapeutics
- DBV Technologies
- Regeneron Pharmaceuticals
- Thermo Fisher Scientific
- ALK Abello
- Mast Group
- Food Allergy Research & Education (FARE)
- Asthma and Allergy Foundation of America (AAFA)
Recent News:
- The United States Food and Drug Administration approved Xolair (omalizumab) injection in February 2024 for immunoglobulin E-mediated food allergy in confident adults and children aged one year and up, to reduce allergic reactions (Type I), including the risk of anaphylaxis, caused by accidental exposure to one or more foods. Patients on Xolair must continue to avoid foods they are allergic to. Xolair is intended for recurrent use to reduce the risk of allergic reactions; however, it is not approved for the immediate treatment of allergic reactions, such as anaphylaxis.